ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Other Long Term Assets: kr5.78 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EXPRS2 ExpreS2ion Biotech Holding AB OSTO:EXPRS2
43 GF Score
Price kr1.30
GF Value kr2.99
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Other Long Term Assets?

ExpreS2ion Biotech Holding AB OSTO:EXPRS2 +4.42% 43 Other Long Term Assets is kr5.78 Mil as of Jun. 2026. GuruFocus rates OSTO:EXPRS2 with a GF Score™ of 43/100 and a GF Value™ of kr2.99 (Possible Value Trap). The stock has 4 warning signs investors should review.

ExpreS2ion Biotech Holding AB's other long-term assets for the quarter that ended in Jun. 2026 was kr5.78 Mil.

ExpreS2ion Biotech Holding AB's quarterly other long-term assets increased from Dec. 2025 (kr5.61 Mil) to Mar. 2026 (kr5.71 Mil) and increased from Mar. 2026 (kr5.71 Mil) to Jun. 2026 (kr5.78 Mil).

ExpreS2ion Biotech Holding AB's annual other long-term assets increased from Dec. 2023 (kr5.80 Mil) to Dec. 2024 (kr5.93 Mil) but then declined from Dec. 2024 (kr5.93 Mil) to Dec. 2025 (kr5.61 Mil).

ExpreS2ion Biotech Holding AB Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB Other Long Term Assets Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.14 1.56 5.80 5.93 5.61

ExpreS2ion Biotech Holding AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.79 5.74 5.61 5.71 5.78
OSTO:EXPRS2
43GF Score
ExpreS2ion Biotech Holding AB OSTO:EXPRS2
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of kr5.78 Mil mean?
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Other Long Term Assets of kr5.78 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Other Long Term Assets too high?
ExpreS2ion Biotech Holding AB's current Other Long Term Assets is kr5.78 Mil. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Other Long Term Assets compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Other Long Term Assets of kr5.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Other Long Term Assets is kr5.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.99, compared to a current price of kr1.30 — trading 56.5% below its estimated fair value. The current Other Long Term Assets is kr5.78 Mil. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Other Long Term Assets is kr5.78 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of kr1.30 is trading 56.5% below its estimated GF Value™ of kr2.99. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for OSTO:EXPRS2:

  • Other Long Term Assets: kr5.78 Mil
  • GF Value™: kr2.99 vs. price of kr1.30 (56.5% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ExpreS2ion Biotech Holding AB Business Description

Other Exchanges 5JD0:Germany
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score

Get the complete analysis for OSTO:EXPRS2

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.30
Price
kr2.99
GF Value